Lexeo wins FDA RMAT designation for LX2020 in PKP2 arrhythmogenic cardiomyopathy
Reuters2026/08/05 11:39- Lexeo Therapeutics won FDA RMAT designation for LX2020, an AAV gene therapy for PKP2-associated arrhythmogenic cardiomyopathy.
- Designation was supported by interim data from the ongoing Phase I/II HEROIC-PKP2 trial.
- LX2020 also holds FDA Orphan Drug, Fast Track designations, supporting an expedited development path.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
UBS lowers Ciena target price to $394
EUR/USD Price Forecast: Holds key 100-day SMA at start of the US CPI week
Malaysia Govt Spending Plan Could Help 99 Speed Mart Retail -- Market Talk
Paying the price for supporting the yen? Japan's foreign reserves fell by $87.8 billions in August, possibly due to selling US Treasuries for funding.
Japanese authorities may have used part of their foreign exchange reserves, including foreign securities such as U.S. Treasury bonds, over the past month to fund record-sized foreign exchange intervention operations.
Crypto prices
More
